Randomised controlled study on the effects of imiquimod, a TLR 7 activating agent, on the HPV16-specific immune response following HPV16 E6/E7 synthetic long peptides vaccination in women with HPV16 positive high grade vulvar/vaginal intraepithelial neoplasia grade III

Trial Profile

Randomised controlled study on the effects of imiquimod, a TLR 7 activating agent, on the HPV16-specific immune response following HPV16 E6/E7 synthetic long peptides vaccination in women with HPV16 positive high grade vulvar/vaginal intraepithelial neoplasia grade III

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Apr 2016

At a glance

  • Drugs ISA 101 (Primary) ; Imiquimod
  • Indications Human papillomavirus infections; Vulvar intraepithelial neoplasia
  • Focus Pharmacodynamics; Proof of concept
  • Most Recent Events

    • 14 Apr 2016 Results published in the journal Clinical Cancer Research, according to an ISA Pharmaceuticals media release.
    • 24 Feb 2014 According to an ISA Pharmaceuticals media release, the status of this trial is completed.
    • 01 Jan 2014 Status changed from recruiting to suspended.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top